CD8A and neoplasm: We performed bulk TCRβ sequencing on sorted CD4+ and CD8+ TILs from bilateral AB1-HA tumors treated with anti-CTLA-4 and anti-OX-40 ICT because we previously observed robust anti-tumor effects with this combination (Figure 2(a,b)).22 Bilateral tumors were harvested when sizes between ICT and control groups were similar for both flanks (Figure 2(b), Supp Figure S3A).